$14.90
▼ -2.0% Today
as of Sep 4, 16:45 ET
Last 30 days
Recent Press Releases & News
AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?
AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027
Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
Overview
52-week range
$9.39
$16
80% of range
Avg surprise (last 3)
+24.1%
Avg reaction (last 1)
-10.2%
0% positive
Latest IV / EM
100%
EM ±16.6% · $15 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Sat Feb 28, 2026 | Feb 2026 | $-0.19 | — | — | — | — | financials |
| Thu Oct 2, 2025 | Aug/2025 | $-0.10 | $-0.14 | +28.6% | — | — | earnings |
| Tue Jul 15, 2025 | May/2025 | $-0.03 | $-0.13 | +76.9% | — | -10.2% | earnings |
| Fri Feb 28, 2025 | Feb 2025 | $-0.11 | — | — | — | — | financials |
| Sat Nov 30, 2024 | Nov 2024 | $-0.26 | — | — | — | — | financials |
| Sat Aug 31, 2024 | Aug 2024 | $-0.31 | — | — | — | — | financials |
| Thu Feb 29, 2024 | Feb 2024 | $-4.67 | — | — | — | — | financials |
| Thu Nov 30, 2023 | Nov 2023 | $-0.72 | — | — | — | — | financials |
| Wed Jul 12, 2023 | May/2023 | $0.02 | $0.03 | -33.3% | — | — | earnings |
| Tue Feb 28, 2023 | Feb 2023 | $-0.24 | — | — | — | — | financials |
| Wed Nov 30, 2022 | Nov 2022 | $-0.21 | — | — | — | — | financials |
| Wed Aug 31, 2022 | Aug 2022 | $-0.33 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Oct 1, 2026 | Aug/2026 | OTHER | -$0.10 | -$0.10 | 0.0% |
Financials
Income statement (quarterly)
| Metric | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $78M | $79M | $76M | — | $72M | $73M | $67M | — |
| Cost of revenue | $37M | $35M | $34M | — | $33M | $33M | $31M | — |
| Gross profit | $41M | $45M | $42M | — | $39M | $40M | $37M | — |
| Operating income | $-13M | $-6M | $-11M | — | $-10M | $-11M | $-13M | — |
| Net income | $-8M | $-6M | $-11M | — | $-4M | $-11M | $-13M | — |
| EPS (diluted) | $-0.19 | $-0.15 | $-0.26 | — | $-0.11 | $-0.26 | $-0.31 | — |
Balance sheet (quarterly)
| Metric | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $38M | $42M | $39M | $56M | $45M | $54M | $55M | $76M |
| Inventory | $59M | $66M | $62M | $62M | $63M | $66M | $65M | $61M |
| Total current assets | $156M | $161M | $157M | $168M | $172M | $175M | $173M | $193M |
| Total assets | $261M | $270M | $266M | $280M | $285M | $292M | $294M | $318M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $87M | $93M | $87M | $97M | $100M | $105M | $97M | $112M |
| Total equity | $173M | $176M | $179M | $183M | $186M | $187M | $197M | $206M |